Three papers on clinical trials with statin drugs, published in 2004–2006, imply that the observed improvement in selected trial endpoints result from gross reductions in serum total cholesterol (TC) and cholesterol carried by low-density lipoprotein (LDL-C), despite evidence to the contrary, which was not cited in these papers.